Cue Biopharma is trading at $22.77 (-5.05%) after Purcell & Lefkowitz announced a shareholder investigation into recent corporate actions.
- Wall Street Zen downgraded the company from hold to sell, adding negative analyst sentiment.
- Cue Biopharma reported a second-quarter net loss of $24.14 per share, despite stronger revenue.
- Shares fell -19.18% on August 17 and -6.35% on August 20; trading is active during the open session, but volume data was unavailable.